RxDoctor Payments Data

Joseph Bacak, MD

Internal Medicine · Fountain Hill, PANPI 1245207034

Payments from drug & device makers

$1,885in general payments, 2019–2025

Across 130 payments — averaging $14.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$569
  • Novo Nordisk$365
  • Amgen$224
  • Boehringer Ingelheim$144
  • Exact Sciences$131
  • AstraZeneca$107
  • plus $344 from 7 others

What the payments were for

  • Food & beverage$1,885100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC49$569
Novo Nordisk23$365
Amgen13$224
Boehringer Ingelheim9$144
Exact Sciences8$131
AstraZeneca6$107
AbbVie(2 entities)7$100
Pfizer4$62
GSK3$43
Novartis2$42
Sanofi Pasteur Inc.2$40
Seqirus USA Inc2$32
Abbott2$27

How this compares

$1,885 in reported general payments places this provider in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$177,187
Medicare patients
411
Services billed
2,106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin223$289,146
EliquisApixaban134$153,018
TrulicityDulaglutide33$53,398
OzempicSemaglutide34$32,620
XareltoRivaroxaban20$22,249
MyrbetriqMirabegron11$13,167
RybelsusSemaglutide13$12,390
Arnuity ElliptaFluticasone Furoate32$10,563
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$8,806
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$7,912
Atorvastatin Calcium541$6,515
Losartan Potassium500$6,323
DapagliflozinDapagliflozin Propanediol12$5,870
Metoprolol Succinate283$5,744
Levothyroxine Sodium314$5,376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$144$289,146223 claims
PfizerEliquis$62$153,018134 claims
Lilly USA, LLCTrulicity, Olanzapine$569$54,71047 claims
Novo NordiskOzempic, Rybelsus$365$45,01147 claims
GSKArnuity Ellipta$43$10,56332 claims
AbbVieSynthroid$100$4,66175 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Fountain Hill

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →